Bavarian Nordic A/S today announced the appointment of Henrik Juuel to the position of Executive Vice President and Chief Financial Officer. Mr. Juuel is currently the CFO of Orexo AB.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_online_appointment_juuel.jpg420420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-05-31 16:29:422018-05-31 16:29:42Bavarian Nordic to appoint Henrik Juuel as CFO
Brain disease specialist Denali Therapeutics will buy all outstanding shares in British F-Star Gamma Ltd from F-Star instead licencing bispecific antibody candidates that can cross the blood-brain barrier (BBB) co-developed under an agreement dating back to 2016.
Nordic Nanovector ASA today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the companys Annual General Meeting on 30 May 2018.
Roche announced that atezolimumab plus chemotherapy met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) as first-line treatment of stage IV nonsquamous non small cell lung cancer (NSCLC).
Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).
https://european-biotechnology.com/wp-content/uploads/2024/04/nouscom_woolfson.jpg270270h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-05-29 13:40:152018-05-29 13:40:15Nouscom Appoints Adrian Woolfson as CMO
Following reports of an increase in mortality in a study that combined Genmabs anti-CD38 daratumumab with a PD-L1 blocker, Genmabs partner Janssen has stopped a study combining daratumumab with its PD1 blocker JNJ-63723283 in multiple myeloma.
Targovax ASAs cancer immunotherapy TG01 significantly prolonged 2-year overall survival of patients with resected pancreatic cancer versus standard therapy. Targovax shares were up 16% on Thursday evening.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2018-05-25_um_05.06.54.png548665Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-05-24 13:52:532018-05-24 13:52:53Targovax drug boosts 2-year OS in pancreatic cancer
Vifor Fresenius Medical Care Renal Pharma has licenced ex-US/Japanese/Korean rights to commercialise CR845 (difelikefalin) from Cara Therapeutics for the treatment of chronic kidney disease-associated pruritus (CKD-aP).
Bavarian Nordic to appoint Henrik Juuel as CFO
AppointmentsBavarian Nordic A/S today announced the appointment of Henrik Juuel to the position of Executive Vice President and Chief Financial Officer. Mr. Juuel is currently the CFO of Orexo AB.
Denali bags F-Star Gamma
Latest NewsBrain disease specialist Denali Therapeutics will buy all outstanding shares in British F-Star Gamma Ltd from F-Star instead licencing bispecific antibody candidates that can cross the blood-brain barrier (BBB) co-developed under an agreement dating back to 2016.
Rainer Boehm joins Nordic Nanovector Board of Directors
AppointmentsNordic Nanovector ASA today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the companys Annual General Meeting on 30 May 2018.
Roche mets endpoints in first-line NSCLC study
Latest NewsRoche announced that atezolimumab plus chemotherapy met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) as first-line treatment of stage IV nonsquamous non small cell lung cancer (NSCLC).
Nouscom Appoints Adrian Woolfson as CMO
AppointmentsNouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).
New way to safer CAR-T cell therapies
Latest NewsInterleukin 1 (IL-1) blockers may prevent serious adverse events triggered by CAR-T cell therapies, according to two independent studies.
Janssen ends combo with daratumumab
Latest NewsFollowing reports of an increase in mortality in a study that combined Genmabs anti-CD38 daratumumab with a PD-L1 blocker, Genmabs partner Janssen has stopped a study combining daratumumab with its PD1 blocker JNJ-63723283 in multiple myeloma.
Targovax drug boosts 2-year OS in pancreatic cancer
Latest NewsTargovax ASAs cancer immunotherapy TG01 significantly prolonged 2-year overall survival of patients with resected pancreatic cancer versus standard therapy. Targovax shares were up 16% on Thursday evening.
Researchers target metastases
Latest NewsItalian oncologists have found a more effective tumour angiogenesis blocker which curbs metastasis and tumour growth.
Vifor Pharma in €70m pruritus drug deal
Latest NewsVifor Fresenius Medical Care Renal Pharma has licenced ex-US/Japanese/Korean rights to commercialise CR845 (difelikefalin) from Cara Therapeutics for the treatment of chronic kidney disease-associated pruritus (CKD-aP).